Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Burns D002056 34 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Infertility, Male D007248 11 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Brain Injuries D001930 4 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Hopkins NK et al. Acetyl glyceryl ether phosphorylcholine (PAF-acether) and leukotriene B4-mediated neutrophil chemotaxis through an intact endothelial cell monolayer. 1984 Biochim. Biophys. Acta pmid:6089913
Emilsson A and Sundler R Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and ionophore A23187. 1984 J. Biol. Chem. pmid:6321496
Krishnamurthi S et al. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. 1984 Biochem. Pharmacol. pmid:6091666
Kamitani T et al. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. 1984 Eur. J. Pharmacol. pmid:6144557
Tokumura A et al. Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. 1984 J. Pharm. Pharmacol. pmid:6144763
Pirotzky E et al. Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. 1984 Kidney Int. pmid:6144811
Rao AK et al. Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. 1984 Am. J. Hematol. pmid:6431801
Colditz IG and Movat HZ Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. 1984 J. Immunol. pmid:6088633
Siess W et al. Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change. 1984 J. Biol. Chem. pmid:6429141
Knauer KA et al. Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6200443
Kazimierczak W et al. Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. 1984 Am. Rev. Respir. Dis. pmid:6201094
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Mallet AI et al. Rapid isocratic high-performance liquid chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. 1984 J. Chromatogr. pmid:6480761
Kenzora JL et al. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. 1984 J. Clin. Invest. pmid:6480824
Jackson EM et al. High performance liquid chromatography of platelet-activating factors. 1984 J. Lipid Res. pmid:6481248
Dewar A et al. Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig. 1984 J. Pathol. pmid:6481526
Goldstein BM et al. Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. 1984 Life Sci. pmid:6482659
Baldo BA and Tovey ER Allergy, allergens and allergen standardization. 1984 Med. J. Aust. pmid:6482786
Caramelo C et al. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. 1984 Biochem. Biophys. Res. Commun. pmid:6732788
Lenihan DJ and Lee TC Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6732789
Kasuya Y et al. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. 1984 Can. J. Physiol. Pharmacol. pmid:6733593
Page CP et al. Platelets and bronchospasm. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6735490
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Levi R et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. 1984 Circ. Res. pmid:6692502
Humphrey DM et al. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. 1984 Lab. Invest. pmid:6694349
Masugi F et al. Effect of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the rat. 1984 Life Sci. pmid:6694519
Bottecchia D et al. Influence of the pure synthetic PAF (platelet aggregating factor) on clot retraction and platelet aggregation. 1984 Scand J Haematol pmid:6695148
Blank ML et al. A new class of antihypertensive neutral lipid: 1-alkyl-2-acetyl-sn-glycerols, a precursor of platelet activating factor. 1984 Biochem. Biophys. Res. Commun. pmid:6696762
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Guay DR and Richard A Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. 1984 Drug Intell Clin Pharm pmid:6723517
Poitevin B et al. Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. 1984 Immunopharmacology pmid:6724877
Kasuya Y et al. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). 1984 J. Pharmacobio-dyn. pmid:6726619
McGivern DV and Basran GS Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in man. 1984 Eur. J. Pharmacol. pmid:6592097
Beaubien BB et al. Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. 1984 Biochem. Biophys. Res. Commun. pmid:6594998
Roubin R et al. The role of immunomodulators in the production of lipid mediators by macrophages (M phi). 1984 Int J Tissue React pmid:6596298
Nishihira J et al. Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. 1984 Lipids pmid:6527609
Lefer AM et al. Pathophysiological mechanisms of sudden death induced by platelet activating factor. 1984 Br. J. Pharmacol. pmid:6435705
Gunby P A new piece for the puzzle of inflammation. 1984 JAMA pmid:6420583
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930
Mojarad M et al. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. 1983 May-Jun Bull Eur Physiopathol Respir pmid:6882949
Pazzi A et al. [Platelet activation in vivo. Electron microscopy study of a case of type II diabetes]. 1983 Mar-Apr G Clin Med pmid:6884636
Satouchi K et al. Application of selected ion monitoring to determination of platelet-activating factor. 1983 J. Biochem. pmid:6423622
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Camussi G et al. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. 1983 J. Immunol. pmid:6311899
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Sano K et al. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. 1983 J. Biol. Chem. pmid:6218169
Vargaftig BB et al. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221558
Voelkel NF et al. Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221590
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Keraly CL et al. Effect of structural analogues of PAF-acether on platelet desensitization. 1983 Br. J. Haematol. pmid:6824590
Tence M et al. The enantiomer and the positional isomer of platelet-activating factor. 1983 Biochim. Biophys. Acta pmid:6824744
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Holt PG et al. Platelet serotonin release by human polymorphonuclear leucocytes stimulated by cotton dust bacteria. 1983 Clin. Exp. Immunol. pmid:6831770
McDonald TP and Kalmaz GD Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. 1983 Exp. Hematol. pmid:6832243
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Levy JV Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. 1983 FEBS Lett. pmid:6832368
Touqui L et al. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. 1983 Biochem. Biophys. Res. Commun. pmid:6838557
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Levy JV Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. 1983 Proc. Soc. Exp. Biol. Med. pmid:6844347
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
O'Flaherty JT et al. Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. 1983 Res. Commun. Chem. Pathol. Pharmacol. pmid:6844746
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
Tiffany ML Technical considerations for platelet aggregation and related problems. 1983 Crit Rev Clin Lab Sci pmid:6370596
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992